Premium
A double‐blind placebo‐controlled trial of BRL 24924 on lower oesophageal sphincter pressure and gastro‐oesophageal reflux in healthy volunteers
Author(s) -
ROBERTSON C. S.,
EVANS D. F.,
HICKS F.,
ATKINSON M.
Publication year - 1988
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/j.1365-2036.1988.tb00723.x
Subject(s) - medicine , reflux , placebo , metoclopramide , gastroenterology , esophagus , gastro , anesthesia , vomiting , alternative medicine , disease , pathology
SUMMARY BRL 24924 is a new gastrointestinal prokinetic agent with properties similar to metoclopramide but with increased potency and devoid of side‐effects associated with blockade of dopamine receptors in the central nervous system. A double‐blind placebo‐controlled trial of the effect of a single oral dose of 2.2 mg BRL 24924 on lower oesophageal sphincter pressure and gastro‐oesophageal reflux has been performed in 20 healthy volunteers. BRL 24924 significantly increased mean lower oesophageal sphincter pressure (21.9 cmH 2 O BRL; 15.9 cmH 2 O placebo: P < 0.017) but failed to alter either the frequency or the duration of gastrooesophageal reflux after provocation following a test meal. BRL 24924 has significant effects on lower oesophageal sphincter pressure but no effect on provoked post‐prandial reflux in healthy volunteers. Further studies in patients with gastro‐oesophageal reflux and oesophagitis are needed to evaluate the clinical efficacy of this compound.